Guest Editors
Dr. Hui Lu
Email: huilu@zju.edu.cn
Affiliation: The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China.
Homepage:
Research Interests: advanced molecular imaging, novel imaging probes, multimodal imaging strategies, early prostate cancer detection, treatment monitoring, tissue engineering, biomaterials, hydrogels, 3d-printed scaffolds, cancer modeling, targeted drug delivery, regenerative applications
Dr. zhenfeng Liu
Email: zhenfeng19792003@zju.edu.cn
Affiliation: Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University
Research Interests: PSMA-targeted molecular imaging agents, radioligand therapy (rlt), sensitization strategies, nanotechnology, theranostics, prostate cancer
Dr. Dengfeng Cheng
Email: cdflyx@163.com
Affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Homepage:
Research Interests: medical imaging, nuclear medicine, R&D of radiopharmaceuticals
Dr. Zhijie Xu
Email: xuzj@zju.edu.cn
Affiliation: Department of Urology,The First Affiliated Hospital, Zhejiang University
Research Interests: precision diagnosis, personalized treatment, prostate cancer
Summary
Prostate cancer remains a leading cause of cancer-related deaths worldwide, necessitating more precise diagnostic and therapeutic strategies. Molecular imaging, particularly PSMA-targeted PET/SPECT, has revolutionized prostate cancer detection and staging, enabling earlier and more accurate diagnosis. Additionally, PSMA-targeted radioligand therapy (RLT) has emerged as a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Meanwhile, nanotechnology and advanced biomaterials are enhancing drug delivery, theranostics, and multimodal imaging, further improving patient outcomes. This Special Issue will explore cutting-edge research integrating nuclear medicine, molecular imaging, and nanomedicine to advance prostate cancer diagnosis and therapy.
Scope and Themes:
Including but not limit to:
-PSMA-targeted imaging and radioligand therapy
-Novel radiopharmaceuticals and theranostic agents
-Nanoparticle-based drug delivery and imaging
-Molecular imaging for disease progression and treatment monitoring
-Clinical translation and personalized treatment strategies
This Special Issue aims to bridge fundamental research with clinical applications, highlighting innovative approaches to improve prostate cancer management and drive future advancements in precision oncology.
Keywords
PSMA-targeted imaging, radioligand therapy, prostate cancer, molecular imaging, nuclear medicine, theranostics, nanoparticles, PET/SPECT, drug delivery, precision oncology
Login
Register
Submit a Paper
Propose a Special lssue